Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-09-05
2006-09-05
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S538000, C514S450000, C514S452000, C514S456000, C514S466000, C514S469000, C514S470000, C514S471000, C549S229000, C549S267000, C549S274000, C549S436000, C549S438000, C549S444000, C549S304000, C549S310000, C549S292000, C549S313000, C558S269000, C560S034000
Reexamination Certificate
active
07101912
ABSTRACT:
Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.
REFERENCES:
patent: 2996341 (1961-08-01), Barry
patent: 3139383 (1964-06-01), Neville
patent: 3402240 (1968-09-01), Cain et al.
patent: 3462536 (1969-08-01), Chemerda et al.
patent: 3676480 (1972-07-01), Sletzinger et al.
patent: 3715382 (1973-02-01), Karady et al.
patent: 3746753 (1973-07-01), Karady et al.
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4051251 (1977-09-01), Stone
patent: 4055645 (1977-10-01), Scriabine
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4156734 (1979-05-01), Stone
patent: 4200098 (1980-04-01), Ayer et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4313956 (1982-02-01), Bodor et al.
patent: 4421736 (1983-12-01), Walters
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4663349 (1987-05-01), Repta
patent: 4721613 (1988-01-01), Urquhart et al.
patent: 4752470 (1988-06-01), Mehta
patent: 4771073 (1988-09-01), Repta
patent: 4816263 (1989-03-01), Ayer et al.
patent: 4820523 (1989-04-01), Shtohryn et al.
patent: 4826875 (1989-05-01), Chiesi
patent: 4853229 (1989-08-01), Theeuwes
patent: 4873263 (1989-10-01), Repta
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 6051576 (2000-04-01), Ashton et al.
patent: 6171615 (2001-01-01), Roussin et al.
patent: 6375987 (2002-04-01), Farah et al.
patent: 6379700 (2002-04-01), Joachim et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 919691 (1973-01-01), None
patent: 929483 (1973-07-01), None
patent: 951661 (1974-07-01), None
patent: 951662 (1974-07-01), None
patent: 956969 (1974-10-01), None
patent: 971974 (1975-07-01), None
patent: 2 062 285 (1971-07-01), None
patent: 20 62 285 (1971-07-01), None
patent: 230 865 (1985-12-01), None
patent: 240 818 (1986-11-01), None
patent: 240 818 (1986-11-01), None
patent: 0 309 827 (1989-04-01), None
patent: 1 261 660 (1972-01-01), None
patent: 1 343 408 (1974-01-01), None
patent: 60-11448 (1985-01-01), None
patent: WO 95/20567 (1995-08-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 02/34237 (2002-05-01), None
International Search Report for PCT/US03/38742, dated Mar. 30, 2004 (5 pages).
Cheng and Fung, “Dose-Dependent Pharmacokinetics of Laevodopa and its Metabolites in the Rat,”Xenobiotica, 6(4):237-248 (1976).
Kurlan et al., “Duodenal and Gastric Delivery of Levodopa in Parkinsonism,”Ann. Neurol., 23(6):589-595 (1988).
Iwamoto et al., “Effect of Age on Gastrointestinal and Hepatic First-Pass Effects of levodopa in Rats,”J. Pharm. Pharmacol., 39:421-425 (1987).
Entry on Sinemet® inPhysicians' Desk Reference, 56th Edition (2002).
Yeh et al., “Pharmacokinetics and Bioavailability of Sinemet CR: A Summary of Human Studies,”Neurology, 39(Suppl. 2):25-38 (1989).
Sandler et al., “Variation of Levodopa Metabolism with Gastrointestinal-Absorption Site,”The Lancet, 1(7851):238-240 (1974).
“SkyePharma's Medopar-DR approved,”Scrip, 2233:21 (1997).
Juncos et al., “Levodopa Methyl Ester Treatment of Parkinson's Disease,”Neurology, 37:1242-1245 (1987).
Cooper et al., “L-Dopa Esters as Potential Prodrugs: Effect on Brain Concentration of Dopamine Metabolites in Reserpinized Mice,”J. Pharm. Pharmacol., 39:809-818 (1987).
Graul, “The Year's New Drugs,”Drug News Perspect., 14(1):12-31 (2001).
Fix et al., “Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption,”Pharm. Res., 6(6):501-505 (1989).
Fix et al., “A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice,”Pharm. Res., 7(4):384-387 (1990).
Leppert et al., “ The Effects of Carbidopa Dose and Time and Route of Administration on Systemic L-Dopa Levels in Rats,”Pharm. Res., 5(9):587-591 (1988).
Contin et al., “Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease,”Clin. Pharmakinet., 30(6):463-481 (1996).
Lu and Yu, “Dimensionless Presentation for Drug Release from a Coated Pure Drug Bead: 2. Experiment, ”Int. J. Pharm., 112:117-124 (1994).
Felmeister, “Powders,” inRemington's Pharmaceutical Sciences, Mack Publishing Company, Fourteenth Edition, Chapter 86, pp. 1626-1628 (1970).
Fincher, “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci., 57(11):1825-1835 (1968).
King and Schwartz, “Oral Solid Dosage Forms,” inRemington's Pharmaceutical Sciences, Mack Publishing Company, Chapter 90, pp. 1603-1625 (1985).
Sefton, “Implantable Pumps,”CRC Crit. Rev. Biomed. Eng., 14(3):201-240 (1987).
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”N. Engl. J. Med., 321(9):574-579 (1989).
Langer and Peppas, “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”J. Macromol. Sci. Rev. Macromol Chem. Phys., C23(1):61-126 (1983).
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science, 228:190-192 (1985).
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant:In VivoCharacterization,”Ann. Neurol., 25:351-356 (1989).
Howard et al, “Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,”J. Neurosurg., 71:105-112 (1989).
Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms,”Int. J. Pharm. Tech.&Prod. Mfr., 5(3):1-9 (1984).
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm., 2:307-315 (1979).
Goodson, “Dental Applications” inMedical Applications of Controlled Release, vol. II: Applications and Evaluation, Langer and Wise (Eds.), CRC Press, Inc., Chapter 6, pp. 115-138 (1984).
Langer, “New Methods of Drug Delivery,”Science, 249:1527-1533 (1990).
Linhardt, “Biodegradable Polymers for Controlled Release of Drugs,” inControlled Release of Drugs: Polymers and Aggregate Systems, Rosoff (Ed.), VCH Publishers, Chapter 2, pp. 53-95 (1989).
Coleman et al., “Polymer Reviews: A Practical Guide to Polymer Miscibility,”Polymer, 31:1187-1203 (1990).
Hoes and Feijen, “The Application of Drug-Polymer Conjugates in Chemotherapy,” inHorizons in Biochemistry and Biophysics, vol. 9: Drug Carrier Systems, Roerdink and Kroon (Eds.), John Wiley & Sons, Chapter 3, pp. 57-109 (1989).
Leong and Langer, “Polymeric Controlled Drug Delivery,”Adv. Drug Delivery Rev., 1:199-233 (1987).
Verma et al., “Osmotically Controlled Oral Drug Delivery,”Drug Dev. Ind. Pharm., 26(7):695-708 (2000).
Bhat Laxminarayan
Cundy Kenneth C.
Gallop Mark A.
Li Jianhua
Xiang Jia-Ning
Dentz Bernard
Finnegan Henderson Farabow Garrett & Dunner LLP
XenoPort, Inc.
LandOfFree
Carbidopa prodrugs and derivatives, and compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbidopa prodrugs and derivatives, and compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbidopa prodrugs and derivatives, and compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543353